NGM Bio’s aldafermin shows favourable profile in Phase II NASH study
Aldafermin is being developed as a daily treatment for non-alcoholic steatohepatitis. Credit: Nephron.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more